Receptor editing and genetic variability in human autoreactive B cells

Julie Lang, Takayuki Ota, Margot Kelly, Pamela Strauch, Brian M. Freed, Raul M. Torres, David Nemazee, and Roberta Pelanda

The Rockefeller University Press

The mechanisms by which B cells undergo tolerance, such as receptor editing, clonal deletion, and anergy, have been established in mice. However, corroborating these mechanisms in humans remains challenging. To study how autoreactive human B cells undergo tolerance, we developed a novel humanized mouse model. Mice expressing an anti–human Igκ membrane protein to serve as a ubiquitous neo self-antigen (Ag) were transplanted with a human immune system. By following the fate of self-reactive human κ+ B cells relative to nonautoreactive λ+ cells, we show that tolerance of human B cells occurs at the first site of self-Ag encounter, the bone marrow, via a combination of receptor editing and clonal deletion. Moreover, the amount of available self-Ag and the genetics of the cord blood donor dictate the levels of central tolerance and autoreactive B cells in the periphery. Thus, this model can be useful for studying specific mechanisms of human B cell tolerance and to reveal differences in the extent of this process among human populations.

B lymphocytes are essential cells in establishing immunity, yet are also known contributors to autoimmune diseases. At least half of newly generated B cells are self-reactive (Grandien et al., 1994; Wardemann et al., 2003), and various selection checkpoints are enforced along B cell development and maturation pathways to increase immune function in host defense while preserving self-integrity (Shlomchik, 2008; Goodnow et al., 2010). Over the past several decades, we have acquired a greater understanding of how this selection operates, but more so in mice than in humans. BCR transgenic (Tg) or knock-in mouse models, in which the majority of the B cells harbor a single specificity that can be traced, have greatly aided in elucidating mechanisms of murine B cell selection (reviewed in Goodnow et al., 1995, 2010; Ait-Azzouzene et al., 2004; Pelanda and Torres, 2006, 2012; Kumar and Mohan, 2008; Shlomchik, 2008). These studies have shown that developing, self-reactive mouse B cells have several potential fates: one is to ignore antigen (Ag) if it is either sequestered or at a concentration too low for reactivity, a second is to become anergic (i.e., nonfunctional), a third is to undergo receptor editing, and a fourth is to undergo apoptosis. A fifth fate is to undergo positive selection to low-avidity self-Ags, an outcome accompanied by the differentiation into marginal zone or B1 B cells (Hayakawa et al., 1999; Martin and Kearney, 2000; Wen et al., 2005). Which particular mechanism is invoked depends on both the strength of the signal the self-reactive BCR receives and the developmental state of the cell (Goodnow et al., 1995; Kouskoff et al., 2000; Qian et al., 2001; Ait-Azzouzene et al., 2004; Hippen et al., 2005; Wen et al., 2005; Diaz et al., 2008; Andrews et al., 2013). Moreover, depending on the location of the self-Ag, tolerance is defined as central (i.e., in the bone marrow) or peripheral (i.e., in other tissues).

A criticism of using BCR Tg or knock-in mice for studying B cell selection is that these models hasten B cell development, restrict the B cell repertoire, and, sometimes (e.g., in some conventional Ig Tgs), express nonphysiological levels of BCR. These issues have been addressed by creating mice that express an Igκ reactive self-Ag, enabling studies of tolerance in B cells developing with a wild-type antibody (Ab) repertoire (Ait-Azzouzene et al., 2005). This and other similar Tg models have confirmed that even wild-type murine B cells use deletion, anergy, and receptor editing for the establishment of tolerance (Ait-Azzouzene et al., 2005; Ait-Azzouzene et al., 2006; Duong et al., 2010, 2011; Ota et al., 2011).

The mechanisms that operate in humans to implement B cell tolerance have been more difficult to dissect, as human bone marrow tissue is less readily accessible, and determining the fate of any particular B cell with its own unique specificity is quite challenging. Therefore, human B cell tolerance studies have focused on measuring frequencies of a panel of...
defined autoreactive or polyreactive B cell specificities mainly in the blood and in few bone marrow samples of healthy individuals or patients with autoimmunity (reviewed in Meffre and Wardemann, 2008; Meffre, 2011). Although these studies confirm that selection processes occur during human B cell development and with checkpoints similar to those established in mice, they have done little to determine the exact mechanisms of tolerance induction. This is particularly true for mechanisms of central B cell tolerance.

Immunodeficient mice transplanted with human hematopoietic stem cells (HSCs) provide a tool to study the human immune system in greater depth (Manz and Di Santo, 2009; Ito et al., 2012; Shultz et al., 2012). By using immunodeficient mice of the BALB/c- Rag2<sup>−/−</sup>IL2R<sup>y<sub>−/−</sub></sup> strain (BRG or BALB/c-DKO), we have previously established a robust humanized mouse (hu-mouse) model for the analysis of human B cells and their development (Lang et al., 2011, 2013). Aiming to investigate mechanisms of human B cell tolerance, in this study we modified the BRG strain by introducing a ubiquitous synthetic neo self-Ag reactive with the Igk<sup>+</sup> fraction of human B cells. We then followed the fate of the “self-reactive” human κ<sup>+</sup> cells relative to the nonautoreactive λ<sup>+</sup> cells and measured the level of tolerance induction in animals reconstituted with a human immune system.

The results reveal the phenotype of human B cells while they undergo central tolerance and the mode of tolerance induction. They also indicate that our model can be used to explore differences in tolerance sensitivity among the human population.

**RESULTS**

**Generation of Hck Tg mice**

To study mechanisms of tolerance induction in developing human B cells, we developed a novel Tg mouse model similar to one created to investigate tolerance of wild-type murine B cells (Ait-Azzouzene et al., 2005). The novel transgene, which we refer to as Hck, encodes a membrane-bound neo self-Ag in the form of the single chain Fv anti-human Ig-C<sub>k</sub> HP6053 Ab tethered to a rat IgGl constant region that is in turn linked to an MHC class I transmembrane peptide (Fig. 1 A). A ubiquitin promoter was used to direct the expression of the transgene to all tissues. Two Tg lines (Hck4 and Hck7) were created in a (BALB/c × DBA/2)F<sub>1</sub> genetic background and backcrossed 10 generations onto BALB/c. These mice were then crossed to immunodeficient BRG mice to generate BRG Hck4 and Hck7 animals that lack mouse T, B, and NK cells and can be used as recipients of human immune systems (Traggiai et al., 2004; Legrand et al., 2008; Manz and Di Santo, 2009; Lang et al., 2011). In these Hck<sup>k</sup> hu-mice, human B cells can detect the self-Ag only in trans as the transgene is solely expressed on mouse host cells.

We verified the presence of the transgene on mouse host cells by PCR (not depicted) and measured the extent of its expression by flow cytometric analyses. There was consistently higher expression of the Hck protein in the Hck4 relative to the Hck7 line (Fig. 1 B). Moreover, expression of Hck varied between cell types, being the lowest on GR<sub>1</sub><sup>+</sup> cells, intermediate on nonhematopoietic (mCD45<sup>−</sup>) cells, and the highest on GR<sub>1</sub><sup>−</sup> hematopoietic (mCD45<sup>+</sup>) cells, which are exclusively of myeloid origin in BRG mice. Furthermore, we observed higher Hck Ag expression on liver and kidney cells relative to cells from spleen and bone marrow tissues (Fig. 1 B), with potential implications for the establishment of B cell tolerance. Differential expression of Hck in the two Tg lines was confirmed in bone marrow tissue by immunofluorescent histology (Fig. 1 C). Hck Tg mice of both lines also exhibited soluble Hck protein (cleaved or secreted from cells) in their sera (Fig. 1 D), at concentrations of ∼25 ng/ml. These data demonstrate the establishment of two severely immunodeficient mouse strains expressing on the surface of their cells and in their serum an Ag specific for human κ<sup>+</sup> B cells.

**Igκ<sup>+</sup> human B cells undergo central tolerance in Hck Tg hu-mice**

To test whether Hck could function as a tolerogenic self-Ag, we initially bred Hck (BALB/c × DBA/2) Tg mice to mice that carry a human Ck allele (Casellas et al., 2001) and produced animals in which roughly half of the murine B cell population expressed human Ck, whereas the other half expressed mouse Ck. Flow cytometric analyses indicated a selective absence of human Ck<sup>+</sup> B cells, but not of mouse Ck<sup>+</sup> and λ<sup>+</sup> cells (Fig. 2 A), demonstrating that Hck is specific for the human Ck protein and capable of inducing B cell tolerance.

To investigate the effect of the Hck self-Ag on human B cells, we bred heterozygous Hck<sup>Tg</sup> BRG mice with non-Tg BRG mice to generate litters in which ∼50% of the pups expressed the neo self-Ag. Neonatal (1–3 d old) Hck<sup>+</sup> or non-Tg littermates were transplanted with human CD34<sup>+</sup> HSCs, and the fate of the developing human B cells in the lymphoid organs of adult hu-mice was followed as previously described (Lang et al., 2011, 2013). Human B cells were analyzed by flow cytometry based on the CD19<sup>+</sup> pan-B cell marker. Additionally, CD20 and CD10 were used to differentiate developing B cell subsets in the bone marrow (with CD20<sup>−</sup> being mostly pre-B cells and CD20<sup>+</sup> being mostly immature-transitional B cells) and in the spleen (CD10 is expressed on transitional B cells and not on mature B cells), respectively (Fig. 2 B; Gorantla et al., 2007; Choi et al., 2011; Lang et al., 2013; Villaudy et al., 2014). Initial studies of tolerance were performed with the Hck4 Tg line, which expresses higher levels of the neo self-Ag. We reasoned that if clonal deletion were the overwhelming mechanism of B cell tolerance, we would find a reduction of ∼50% in the number of B cells in Hck<sup>k</sup> mice relative to Hck<sup>−</sup> littermates, especially in the spleen. It is important to preface that the hu-mouse model suffers from extensive variability in the amount of human chimerism (Lang et al., 2011, 2013). In spite of this experimental variability, similar numbers of pre-B (CD19<sup>+</sup>CD20<sup>+</sup>) and immature/transitional (CD20<sup>+</sup>) B cells were observed, on average, in the bone marrow of Hck<sup>+</sup> and Hck<sup>−</sup> hu-mice, suggesting there was no gross arrest in maturation or death of B cells developing in the presence...
of the neo self-Ag (Fig. 2 C). In contrast, the numbers of CD20− B cells in the spleen of Hcκ+ hu-mice were decreased by 30%, on average, relative to those of Hcκ− mice. A similar 30% reduction in cell numbers was observed in the transitional (CD10+) B cell population (Fig. 2 C), suggesting the difference in total B cell numbers was not caused by increased survival or proliferation of mature B cells in Hcκ− hu-mice. Although this difference in transitional B cell numbers was not statistically significant, likely because of extensive variability in chimerism, the lower numbers of B cells in the spleen but not the bone marrow of Hcκ+ hu-mice relative to Hcκ− controls suggests a subset of developing autoreactive B cells underwent clonal deletion between the immature and transitional B cell stages, at a checkpoint that has been previously reported in an equivalent model of murine B cell tolerance (Ait-Azzouzene et al., 2005).

To determine whether autoreactive κ+ B cells were regulated in Hcκ− Tg mice, B cells were tracked by surface staining for κ and λ IgL chains. In Hcκ− control mice, κ to λ cells were in roughly similar proportions, and their ratio did not change with B cell development (Fig. 2, D and F). In the Hcκ+ mice, in contrast, κ IgL chain expression was minimally detected in B cell subsets of both bone marrow and spleen (Fig. 2, D and F). Nevertheless, the proportion of Igλ+ B cells was significantly increased only in the spleen of Hcκ+ hu-mice compared with Hcκ− mice (Fig. 2, D and F). The fact that in the bone marrow the numbers of developing B cells (Fig. 2 C) and the proportion of Igκ+ cells (Fig. 2, D and F) was similar between Hcκ− and Hcκ+ hu-mice suggested that Igκ+ cells were still present but not expressing the BCR on the surface. Indeed, intracellular (IC) staining with anti-human κ Abs revealed a significant population of κ+ B cells in the bone marrow of Hcκ+ mice (Fig. 2 E) that was only slightly smaller than the corresponding population in Hcκ− mice (Fig. 2 F; third and fourth graphs). This was true for both the CD20− cell subset, which comprises a small number of
immature B cells, and the CD20+ B cell subset, which mainly consists of immature and transitional B cells. In contrast, IC κ+ B cells were rare in the spleen of Hcκ+ mice (Fig. 2 F, third graph). These data indicate that κ+ B cells undergo tolerance in response to the neo self-Ag and that most of the tolerance induction occurs centrally, in the bone marrow.

**Human B cells down-regulate CD19 and internalize their BCR during central tolerance**

To characterize the mechanisms of B cell tolerance, we next investigated the phenotype and developmental state of autoreactive human B cells by flow cytometry. We stained bone marrow B cells from Hcκ+ hu-mice for IC κ as well as for the maturation markers BAFFR, CD40, and IgD, to visualize the autoreactive cells and to determine their developmental stage, respectively. During human B cell development, acquisition of CD19 occurs before that of CD20 (Fig. 2 B), whereas expression of BAFFR occurs concomitantly to that of IgM and is followed by the expression of CD40 and IgD, among other developmentally regulated markers (not depicted; Lang et al., 2013). The Igκ+ autoreactive B cells exhibited increased expression of CD40 and BAFFR similar to the expression of nonautoactive (κ− or λ+) immature B cells (Fig. 3 A). In contrast, IgD, which is normally up-regulated on cells past the immature stage, was not expressed on autoreactive B cells (Fig. 3 A). As expected, because of BCR internalization, IgM was also minimally detected on IC κ+ B cells from Hcκ+ mice relative to λ+ cells in the same mice and all B cells in Hcκ− mice (Fig. 3, B and C). In addition, there was a marked down-regulation of CD19 on autoreactive B cells (Fig. 3, D and E). Cumulative results from flow cytometric analyses showed that if a minimum of 10 independent experiments with n = 1–5. Each symbol in C and F represents an individual hu-mouse, and bars are arithmetic means. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
hu-mice relative to Hκκ− hu-mice (Fig. 3 F). Thus, our data indicate that, upon encountering a membrane-bound self-Ag in the bone marrow tissue, human B cells internalize their BCR and down-regulate CD19.

**Human autoreactive B cells undergo receptor editing in hu-mice**

One of the mechanisms of central B cell tolerance in mice is receptor editing, which operates by secondary IgL chain gene recombination events in immature B cells. Characteristics of B cells undergoing editing are increased IgL gene rearrangement, higher expression of Rag1 and Rag2 genes, and lower λB cells undergoing editing are increased Ig gene rearrangement events in immature B cells. Characteristics of receptor editing, which operates by secondary IgL chain gene rearrangement, were confirmed by sequencing the Vλ-Jλκ locus with each Vλ from the Igκ locus with each Vλ and Jκ expression and separated based on the expression of CD20, λ, and ICκ. Representative expression of CD40, BAFFR, and IgD are shown for the indicated B cell subsets. (B–E) Relative expression of IgM (B and C) and CD19 (D and E) on ICκ+ or EC λ+ cells from the indicated populations in the bone marrow of Hκκ− and Hκκ+ hu-mice. The IgM and CD19 MFI values in Hκκ+ mice were normalized to those of the corresponding cell populations in Hκκ− mice analyzed on the same day. (F) Plots show the percentage of human B lineage cells with CD19+ expression in the bone marrow of hu-mice relative to Hκκ− hu-mice. Data are representative of 3–12 independent experiments for each panel with n = 1–5. Each symbol in graphs represents measurements from an individual hu-mouse, and bars show arithmetic means. **, P < 0.001; ***, P < 0.0001.

Figure 3. *Phenotype of autoreactive B cells in the bone marrow of hu-mice.* (A) Human B cells in bone marrow of Hκκ+ hu-mice were gated based on hCD45 and hCD19 expression and separated based on the expression of CD20, λ, and ICκ. Representative expression of CD40, BAFFR, and IgD are shown for the indicated B cell subsets. (B–E) Relative expression of IgM (B and C) and CD19 (D and E) on ICκ+ or EC λ+ cells from the indicated populations in the bone marrow of Hκκ− and Hκκ+ hu-mice. The IgM and CD19 MFI values in Hκκ+ mice were normalized to those of the corresponding cell populations in Hκκ− mice analyzed on the same day. (F) Plots show the gating strategy used to differentiate CD19+ from CD19− B cells in bone marrow. The graph shows the percentage of human B lineage cells with CD19+ expression in the bone marrow of hu-mice relative to Hκκ− hu-mice. Data are representative of 3–12 independent experiments for each panel with n = 1–5. Each symbol in graphs represents measurements from an individual hu-mouse, and bars show arithmetic means. **, P < 0.001; ***, P < 0.0001.

For RAG expression. To determine whether differences in RAG expression were also present when B cells developed in Hκκ− versus Hκκ+ hu-mice, we analyzed gene expression levels in total bone marrow B cells. Indeed, a significant difference in RAG1/2 expression was observed when comparing total bone marrow B cells enriched from Hκκ+ and Hκκ− hu-mice (Fig. 4 C). We further analyzed this cell population to assay Igλ gene rearrangement events with a PCR assay that measures λ excision circles, circular DNA molecules excised from the Igλ locus with each Vλ rearrangement and that remain in B cells as nonreplicating episomes (Fig. 4 D). These circles, moreover, have been shown to correlate with receptor editing in mice (Tiegs et al., 1993; Ait-Azzouzene et al., 2005). Our analysis revealed significantly increased levels of Vλ-Jλκ rearrangements in bone marrow B cells of Hκκ+ hu-mice compared with Hκκ− hu-mice (Fig. 4 E).

Finally, we reasoned that if receptor editing at the Igκ locus was more extensive in Hκκ+ than Hκκ− hu-mice, we should observe altered Vκ and Jκ usage among the Vκ-Jκ rearrangements detected in the λ+ splenic B cell population. Sequencing of the Vκ-Jκ rearrangements from λ+ B cells of Hκκ+ hu-mice revealed significantly increased frequencies of Jκ5 and decreased frequency of Jκ1 relative to those in λ− B cells from Hκκ− hu-mice (Fig. 4 F). This bias usage of proximal and distal Jκ segments is consistent with receptor editing. Moreover, sequences from Hκκ+ hu-mice displayed significantly increased usage of Vk1 gene family members. Overall, results from these analyses indicate that
Figure 4. Receptor editing in human autoreactive B cells. (A) Representative gating of Hcκ- bone marrow cell populations sorted for the analyses of RAG1/2 gene expression. The dump gate represents mCD45+hCD3+hCD11c+ cells. (B) Real-time PCR analysis of RAG1 and RAG2 mRNA levels in B cells enriched from the bone marrow of Hcκ+ and Hcκ- hu-mice. RAG1 and RAG2 levels were first normalized to GAPDH and then to the corresponding RAG1/2 levels of the IgM+CD19- population (set at 1). (C) RAG1 and RAG2 mRNA levels in B cells enriched from the bone marrow of Hcκ- and Hcκ+ hu-mice, indicating that a portion of the Igκ secreted by B cells in Hcκ- hu-mice is removed from the circulation by binding mouse tissue. (D) Relative levels of Vκ-Jκ excision circles and of primers designed to detect them. (E) Relative levels of Vλ-Jλ circles in genomic DNA from B cells enriched from the bone marrow of Hcκ- and Hcκ+ hu-mice. Vκ-Jκ circles signals were normalized to GAPDH levels in each sample. Data in B-E are from three to four independent experiments for each panel and in which RNA or DNA was pooled from one to three hu-mice for each group. (F) Frequency of Vκs (Vκ1, Vκ2, and Vκ3 families) and Jκs in Vκ-Jκ rearrangements cloned from genomic DNA of CD20+ λ+ spleen cells. Cells were sorted from the spleen of Hcκ- and Hcκ+ hu-mice in two independent experiments, with cells pooled from three mice for each sample. The data are from 61 Hcκ- and 66 Hcκ+ individual sequences. Bars in B, C, and E represent mean ± SEM. *, P < 0.05; **, P < 0.001.

Human B cell tolerance in humanized mice | Lang et al.
Dose of self-Ag affects modality and extent of human B cell tolerance

In mice, the mechanisms of B cell tolerance can vary depending on the amount of self-Ag. To test whether similar differences exist in human B cell tolerance, we compared tolerance induction in the Hκκ4 and Hκκ7 Tg lines, which express different levels of self-Ag (Fig. 1). Although we found similar numbers of immature/transitional B cells in the bone marrow and spleen of the two Tg lines, the numbers of CD20+ B cells in the spleen of Hκκ7 hu-mice tended to be lower, on average, than in Hκκ4, but this difference was not statistically significant (Fig. 6 A). However, Hκκ7 splenic B cell numbers were significantly different from those of Hκκ− control mice (Hκκ−: 2.34 × 10⁶ ± 0.43, n = 74; Hκκ7: 1.15 × 10⁶ ± 0.24, n = 39; P = 0.02). In addition, although the proportion of B cells expressing κ on the surface of bone marrow B cells was similar in Hκκ4 and Hκκ7 hu-mice, there was a significant increase in B cells expressing λ in the Hκκ4 hu-mice or expressing ICκ in Hκκ7 hu-mice, both in bone marrow and spleen (Fig. 6 B). Furthermore, a greater and more consistent down-regulation of CD19 was observed in both CD20+ and CD20− B cells from Hκκ4 hu-mice, and this was in spite of similar levels of Igκ internalization in the two Tg lines (Fig. 6 C). In the sera of both Hκκ4 and Hκκ7 hu-mice, similar low levels of Igκ and high levels of Igκ were observed, with a trend of higher λ production in the Hκκ4 line (Fig. 6 D). The reduced frequency of λ+ cells and increased proportion of B cells expressing Igκ intracellularly in Hκκ7 hu-mice suggest a reduced prevalence of receptor editing and increased failure of central tolerance when B cells develop in the presence of lower self-Ag levels. Overall, these data provide evidence that human B cells undergo tolerance with different modalities in the presence of varying levels of self-Ag.

Genetic contribution to human B cell tolerance

Our data indicate that central B cell tolerance mechanisms in human B cells are similar to those established in mouse models (i.e., clonal deletion and receptor editing with associated CD19 and BCR down-regulation). However, through the course of these experiments, we observed considerable variability in tolerance induction among individual hu-mice. We reasoned that genetics of the cord blood (CB) donor might account for some of this variability. To assess the effect of the genetic variability of the donor, we analyzed several tolerance parameters in sets of Hκκ−, Hκκ4, and Hκκ7 hu-mice that were grouped according to their CB donor. We...
further reasoned that if the assay was stringent enough to detect differences in tolerance between CB donors, this difference would be more significant in Hcκ− recipients than in Hcκ+ recipients because a large variation in Hcκ− hu-mice would indicate an inherent assay variability or one less specific to tolerance induction. Using this approach, we found that the number of B cells, the frequency of surface κ+ and λ+ B cells, and the concentration of serum hIgκ had similar variability in Hcκ− and Hcκ+ hu-mice generated with different CBs and, thus, these assays were not sensitive enough to detect differences with respect to tolerance (Fig. 7 A and not depicted). However, the frequencies of B cells displaying ICκ (Fig. 7 B) or low CD19 (Fig. 7 C) were less variable among Hcκ+ recipients and significantly more variable among Hcκ4 and Hcκ7 hu-mice generated with different CB donors. The proportion of CD19+B cells, in particular, showed the largest variation (20–55%) among Hcκ7 hu-mice cohorts, suggesting that the reduced level of self-Ag in Hcκ7 animals provides a higher resolution in resolving individual differences in tolerance induction. To explore this possibility further, we analyzed Hcκ4 and Hcκ7 hu-mice in a scatter plot displaying the frequency of ICκ+ cells in relation to their CD19 MFI. As shown in Fig. 7 D, all Hcκ4 hu-mice fall within a narrow distribution in this scatter plot. In contrast, although some Hcκ7 hu-mice fall within the same Hcκ4 distribution, others are clear outliers, and this distinction depends on the CB donor. Significant differences in tolerance parameters were also observed when comparing most Hcκ− to Hcκ+ hu-mouse groups generated with the same CB, as shown for the percentage of CD19 low cells (Fig. 7 E), suggesting that our model can be used to assess tolerance at the individual level. Overall, our data indicate that Hcκ7 Tg hu-mice can be used to detect and explore differences in B cell tolerance induction in the human population.

**DISCUSSION**

We have used a novel hu-mouse model expressing a human-specific surrogate self-Ag to formally demonstrate that developing human B cells use receptor editing as a mechanism of central B cell tolerance. Central B cell tolerance in hu-mice is stringent but incomplete. Although the selection of autoreactive B cells into the periphery is rare, variations in the extent of tolerance were observed and shown to depend on the amount of self-Ag as well as the individual genetics of the source of CB.

To date, most studies of human B cell tolerance have focused on limited repertoire analyses of B cell subsets present in peripheral blood (Meffre and Wardemann, 2008; Meffre, 2011). These studies have been invaluable in establishing the presence of tolerance checkpoints, but they have been limited to a poorly defined set of self-Ags without a clear understanding of how these Ags directly affect B cells in vivo. In
fact, although a significant reduction in the frequency of autoreactive clones in the human B cell population of the blood relative to the bone marrow has been clearly established, it has not been possible so far to determine whether this, at least in part, is caused by receptor editing, a tolerance mechanism that dominates in the mouse. This is mainly because of an inability to distinguish human autoreactive B cells within the total B cell population. Some studies investigating receptor editing in human B cells have only been able to assess this process indirectly (Wardemann et al., 2004; Schoettler et al., 2012; Kalinina et al., 2014). In other studies, differential levels of recombining sequence rearrangements and of distal Jκ usage in peripheral human B cell populations (Lee et al., 2000; Ng et al., 2004; Panigrahi et al., 2008) have provided stronger support to the presence of receptor editing, but these findings have been highly correlative and did not exclude that a selective process was responsible for the observed repertoires.

Our study differs from those discussed in the previous paragraph by the ability to directly investigate human B cells while they undergo tolerance toward a defined membrane-bound Ag. This feature has allowed us to examine whether human autoreactive B cells display the telltale signs of receptor editing. Indeed, we have observed higher RAG expression and Vλ-Jλ DNA excision circles in bone marrow B cells of hu-mice that express the neo self-Ag (Hcκ+ hu-mice) relative to cells in control animals. Moreover, bona fide autoreactive immature B cells, which we show display low levels of CD19 coreceptor and internalized Igκ BCR, exhibited higher levels of RAG1/2 mRNAs than nonautoreactive immature B cells in the same animals. The phenotype of autoreactive human B cells from Hcκ+ hu-mice is remarkably similar to that of murine immature B cells undergoing receptor editing (Tiegs et al., 1993; Pelanda et al., 1997; Ait-Azzouzene et al., 2005; Verkoczy et al., 2007; Duong et al., 2011). Expression of the Hcκ self-Ag was also associated with a skewing of the Igκ repertoire in peripheral cells. Circulating λ+ B cells normally bear Vk-Jκ rearrangements that are not expressed (even when in-frame) as a result of recombining sequence–mediated inactivation of the Igκ locus (Bräuning et al., 2001), an event that takes place during B cell
development. Therefore, these Vκ-Jκ rearrangements are not subjected to peripheral selection events. The Vκ-Jκ rearrangements isolated from λ+ B cells of Hcκ− hu-mice displayed a reduced use of the proximal Jκ1 and increased use of the distal Jκ5, a finding consistent with an increased frequency of secondary Igκ rearrangements and receptor editing. In addition, these rearrangements displayed increased usage of Vκ1 gene family members relative to controls, suggesting a difference in the rearrangement process of developing autoreactive B cells. The Vκ1 genes (which are the most abundant among Vκs) are interspersed in the Vκ locus, and a bias usage does not provide evidence of progressive secondary recombination events. We compared the usage of distal versus proximal Vκ gene segments (not depicted) without finding a statistically significant difference between sequences isolated from Hcκ+ and Hcκ− hu-mice. We argue, though, that the lack of difference is caused by a the small sample population (around 60 sequences per group) relative to the number of functional Vκ elements (~20 in the Vκ proximal cluster) and the likelihood that receptor editing is also frequent in Hcκ− hu-mice (indeed, CD19+ cells were also observed in the bone marrow of Hcκ− hu-mice). Furthermore, the finding that a fraction of the Vκ-Jκ rearrangements cloned from λ+ B cells of Hcκ+ hu-mice were in-frame (i.e., they expressed a κ chain during B cell development) does not appear to be compatible with “clonal deletion” being the only mechanism of central tolerance. Finally, numbers of transitional B cells were not statistically different in the spleen of Hcκ+ and Hcκ− hu-mice. In their sum, these data demonstrate that human B cells that develop in the bone marrow of hu-mice activate receptor editing upon encountering a membrane-bound self-Ag. In mice it has been shown that whether an individual B cell undergoes a particular tolerance mechanism or a positive selection event into the periphery depends on the BCR affinity for the Ag and the Ag concentration (i.e., the strength of BCR signaling), as well as the developmental state of the B cell when it encounters the self-Ag (Hayakawa et al., 1993; Melamed and Nemazee, 1997). This reasoning suggests that a fraction of autoreactive Igκ+ cells will edit unsuccessfully and consequently undergo cell death, resulting in overall reduced B cell export to the spleen, a prediction consistent with our data.

In spite of the presence of receptor editing during B cell development, there was a (nonstatistically significant) trend toward reduced transitional B cell numbers in the spleen of Hcκ− hu-mice. This difference likely reflects the death of those cells unable to successfully edit their receptors. Clonal deletion as a secondary event has been described in mice when the autoreactivity cannot be easily edited away (Halverson et al., 2004; Ait-Azzouzene et al., 2005; Ait-Azzouzene et al., 2006; Doyle et al., 2006). In our system, all κ+B cells are autoreactive independent of which Vκ they express, and expression of a nonautoreactive BCR requires a productive Vκ-Jκ gene rearrangement, which normally occurs subsequent to the rearrangement of Igκ (Siminovich et al., 1985; Bräuninger et al., 2001; Langerak et al., 2004; Klein et al., 2005). Moreover, Ig gene rearrangements predictably result in out-of-frame V-J gene segments two thirds of the time. Thus, the chance to express a nonautoreactive BCR is unfavorable and likely requires multiple rearrangement attempts and a certain amount of time, which is probably limited (Hartley et al., 1993; Melamed and Nemazee, 1997). This reasoning suggests that a fraction of autoreactive Igκ+ cells will edit unsuccessfully and consequently undergo cell death, resulting in overall reduced B cell export to the spleen, a prediction consistent with our data.

Although we cannot exclude that our observations are valid only when human B cells develop in hu-mice, there are reasons to believe our findings can be generalized to B cells developing physiologically in humans. This is because human B cell development in hu-mice proceeds similarly to that of humans (Lang et al., 2013), and decades of murine studies have indicated that central B cell tolerance is a B cell—intrinsic process (Melamed et al., 1998; Verkoczy et al., 2005; Teodorovic et al., 2014) and, thus, does not require factors expressed by other cell types. Differences have been described in the development of B cells from fetal and adult precursors, with fetal precursors giving rise preferentially to B1a B cells (Yuan et al., 2012; Zhou et al., 2015). Thus, it is possible that our findings are restricted to newborns and hu-mice established with CB-derived HSCs and might not extend to adults and animals generated with HSCs from bone marrow. However, we find this possibility unlikely because of the following reasons: (a) human B cell precursors developing in our hu-mice did not express CD27 (Lang et al., 2013), a marker associated with fetal B cells (McWilliams et al., 2013), and did not prevalently differentiate into B1 cells (unpublished data), and (b) the mouse-specific version of the Hcκ Ag causes negative selection in all B cell compartments, including B1 B cells (Ait-Azzouzene et al., 2005).
and mature cell stages, a checkpoint that has been described in both mice and humans (Wardemann et al., 2003; Andrews et al., 2013). Because of these data and the fact that the great majority of $\kappa^+$ B cells undergo negative selection in all Hc$\kappa^+$ hu-mice, we do not favor the possibility that the few $\kappa^+$ B cells in the periphery of Hc7 hu-mice have undergone a positive selection event. Collectively, these data indicate that, just as described for murine B cells, where and how human B cells undergo tolerance depends on the local concentration of self-Ag, the location of self-Ag, and the developmental state of the B cell when it encounters an effective dose of self-Ag.

In spite of an efficient central B cell tolerance process, small amounts of Ig$\kappa$ were measured in the serum of a minority of Hc$\kappa$ hu-mice, and ELISPOT analyses confirmed the presence of Ig$\kappa$-producing plasmablasts, particularly in older animals. Together, the detection of a few IC $\kappa^+$ splenic B cells, of serum Ig$\kappa$, and of $\kappa$-secreting plasmablasts demonstrate that central B cell tolerance was not absolute in some animals, possibly because of an insufficient concentration of self-Ag in the bone marrow or a defective receptor editing process, which is sometimes observed in mice (Liu et al., 2005; Fournier et al., 2012). In our hu-mouse model, human T cells develop in a mouse thymus and are thought of being educated mostly on mouse MHC (Legrand et al., 2009; Manz and Di Santo, 2009; Tanega and David, 2010; Ito et al., 2012; Shultz et al., 2012; Akkina, 2013). This likely leads to the development of peripheral T cells unable to provide cognate help to human B cells but possibly also to cells that can provide increased bystander help because of strong “allo” TCR response to human MHC. Moreover, many T cells display an activated state in older hu-mice (Lang et al., 2013). The presence of “alloreactive” and activated T cells might explain why autoreactive B cells that escaped central tolerance in Hc$\kappa$ hu-mice did not remain tolerant in the periphery.

In measuring parameters of central B cell tolerance, we found that the expression level of CD19 and the frequency of cells that were CD19$^{low}$ and IC $\kappa^+$ had limited variability in the non-Tg recipients and greatly increased variability in the presence of the Hc$\kappa$ neo self-Ag, indicating this variability reflects differences in tolerance induction. Importantly, the variability in the frequency of CD19$^{low}$ cells and IC $\kappa^+$ cells segregated significantly with the CB donor, suggesting an inherent individual distinction in tolerance induction based on heritable or epigenetic B cell qualities. The differences among CB cohorts were especially notable in Hc7 recipients, which was further demonstrated by plotting the frequency of IC $\kappa^+$ B cells against their CD19 MFI for both Hc4 and Hc7 hu-mice. In Hc4 animals, in which tolerance is more stringent, these parameters were distributed similarly among hu-mice. In contrast, although half of the Hc7 hu-mice had a distribution similar to that of Hc4, the other half had a markedly different distribution. This difference was inherent to the source of CB, suggesting individual variations in tolerance induction. These findings indicate that Hc7 animals, likely because of their lower self-Ag concentration, provide a better resolution of the tolerance abilities of different immune systems. Because Hc7 hu-mice generally showed increased breaking of tolerance, we propose that CB samples displaying noncanonical frequencies and CD19 levels of IC $\kappa^+$ B cells might be less prone to induce receptor editing and more prone to break central B cell tolerance. A comparison of the percentage of CD19$^{low}$ cells for individual CBs between Hc$\kappa^+$ and Hc$\kappa^-$ hu-mice additionally demonstrated individual variations in tolerance, with some samples displaying differences that were weakly or strongly significant and other samples that showed no difference.

In summary, using a novel hematopoietic hu-mouse model, we have been able to define certain characteristics of autoreactive human B cells undergoing tolerance. Similar to mouse autoreactive B cells, human B cells that engage membrane-bound self-Ag in the bone marrow withdraw the BCR from the surface and display lower surface CD19 levels. They also express higher levels of RAG and products of second-ary Ig gene recombination, resulting in a skewed peripheral repertoire. These observations provide a formal and direct demonstration that human bone marrow B cells can use receptor editing during tolerance. In the future, we envision using this information to detect, isolate, and study autoreactive B cells from human bone marrow samples and to use our hu-mouse model system as a tool to investigate and compare the extent of tolerance induction among developing B cells with autoimmune-associated polymorphisms.

**MATERIALS AND METHODS**

**Generation of Hc$\kappa$ Tg mice.** The construction of the Hc$\kappa$ transgene and production of the two Tg mouse lines (Hc4 and Hc7) were as described previously for the similar anti-mouse $\kappa$ Tg mice (Ait-Azzouzene et al., 2005) except that the Fv region of the transgene was from the mouse anti-human $\kappa$ hybridoma HP6053. Pronuclear injection was performed at the Scripps Research Institute Mouse Genetics Core facility using BALB/c × DBA/2 mice. At the Scripps Research Institute, Hc4 and Hc57 mice were bred to Igk$^{\text{mch}}$ mice (donated by M. Nussenzweig, The Rockefeller University, New York, NY; Casellas et al., 2001) for a preliminary analysis. Hc4 and Hc57 mice were shipped to Denver, back-crossed 10 generations to BALB/c, and then backcrossed to BRG mice to generate Hc4 and Hc57 BRG animals. Hc4 and Hc57 BRG mice were bred as heterozygotes with BRG mice to produce litters with $\sim$50% Tg$^+$ pups. Genotyping was performed by PCR on genomic DNA isolated from a tail clip at weaning with primers specific for the Hc$\kappa$ transgene (forward, 5′-GTGGAGGCTGAGATCTGGAGT-3′; reverse, 5′-GGTTCTGAGGCTGTGGTTCAG-3′) using touchdown PCR: 94°C for 1 min, 72°C (–1°C) for 30 s, 72°C for 1 min for 15 cycles and 14 cycles at 94°C for 1 min, 59°C for 30 s, and 72°C for 1 min. Mice were also phenotyped using flow cytometry of blood, spleen, bone marrow, kidney, or liver single-cell suspensions stained with an Ab to rat IgG1 (RG11; BD), a component of the transgene.
Generation of hematopoietic hu-mice. Hcκ Tg–positive and −negative BRG neonates (1–3 d) were transplanted with “heathy” CB CD34+ HSCs to generate hu-mice using a method previously described (Lang et al., 2011, 2013). The CB units were obtained from the University of Colorado Cord Blood Bank at CliniImmune Labs (Aurora, CO) as samples that were rejected as the result of low volume. Investigators in this study were blinded from donor identities, and the experiments were performed in compliance with the NJH and University of Colorado Institutional Review Boards. Blood samples from mice at 7–9 wk of age were analyzed by flow cytometry with Abs to mouse CD45 (mCD45), human CD45, hCD3, hCD5, and hCD20 to determine the amount of human hematopoietic chimerism. Spleen and bone marrow single cell suspensions were prepared from hu-mice euthanized at 7–24 wk after engraftment. Only mice with >5% human chimerism were included in the study.

Abs and flow cytometry. Abs used in flow cytometric analyses were as described in Lang et al. (2011, 2013). Abs specific for mGR1 (RB6-8C5), mH-2D^d (S4-2-12), mCD45 (30-F11), hCD3 (OKT3, HIT3a), hCD5 (UCHT1), hCD34 (581), hCD38 (HB-7), hCD40 (5C3), hCD45 (H130), hCD138 (ML15), hCD268 (11C1), hlgk (MHK-49), hlgk (MHL-38), and hlgM (MHM-88) were from BioLegend. Abs for rat IgG1 (R.G11/39.4), hCD3 (HIT3a), hCD19 (HB19), and hlgM (G20-127) were from BD, and those for hlgk (HP6062) and hlgM (SA-DA4) were from eBioscience. Fab’ goat anti-hlgM was from Protos Immunoresearch. Cells were stained in staining buffer (PBS, 1% BSA, 0.1% Na Azide) and then incubated with either Triton permeabilization buffer (0.5% BSA, 2 mM EDTA, and 0.1% Triton-X 100 in PBS) for 1 h on ice or saponin permeabilization buffer (0.5% BSA and 0.5% saponin in PBS) for 15 min at RT (these methods were interchangeable). Cells were then stained with Abs for IgM, IgG, Igκ, or Igλ (described in “Abs and flow cytometry”) for 30 min in the dark at RT followed by five washes in staining or saponin buffer.

Histology. Femurs from Hcκ, Hcκ4, and Hcκ7 BRG mice were embedded in Tissue-Tek OCT Compound (Sakura Finetek), frozen immediately on dry ice, and stored at −80°C. Frozen samples were sliced into 4–7-μm sections using a cryoJane adaptation (Leica) on a cryostat and transferred onto glass slides. Slides were dried at RT for a minimum of 30 min, fixed by freezing for 30 min at 50% acetone and then 3 min in 100% acetone. For staining, the slides were rehydrated in PBS for 20 min, blocked with a mixture of anti–mouse CD16 (2G2) Ab, mouse IgG2a (isotype control for the anti–rat IgG1 Ab), and goat serum in PBS, 2% BSA, and 0.05% Tween20 for 15 min at RT and then stained with DAPI, allophtyocyanin-conjugated anti–mouse Gr1, and eFluor 615–conjugated anti–rat IgG1 Abs for 45 min at RT in the dark. After three washes in PBS, dried sections were mounted with a coverslip (# 1.5 thickness) using Fluoromount G (SouthernBiotech) and sealed with nail polish. Sections were visualized on an Eclipse TE 2000 microscope (Nikon) outfitted with a Plan Fluor ELWD Ph2 DM 40× objective dry with a 10× eyepiece for a total 400× magnification. Images were collected using a wide field lens and NIS Elements version 4.2 software and viewed with NIS Elements Viewer version 4.11.0 software (all from Nikon). No deconvolution or 3D reconstructions were performed, and fluoro- chrome settings were set to equivalent intensities among all samples for comparison and analysis. In addition, all files were exported using equivalent settings and file formats.

ELISAs. Total, κ-containing, or λ-containing hlgM and hlgG were measured in the sera of hu-mice with monoclonal Abs purchased from SouthernBiotech. Plates were coated with mouse anti-hlgM (SA-DA4), hlgG (JDC-10), hlgκ (SB81a), and hCD3 for 15 min, washed three times in staining buffer, and then incubated with anti-biotin beads (Miltenyi Biotec) for 15 min in a refrigerator followed by three washes in MACS buffer (1× PBS, 2 mM EDTA, and 0.5% BSA). Cells were loaded on an autoMACS (Miltenyi Biotec) with a “depletes” program. The negative cell fractions were collected, and a sample was stained with Abs for hCD45, mCD45, hCD3, and hCD19 to check purity. All sorted populations were >85% pure.

Cell sorting and enrichment. To sort CD19<sup>hi</sup>lgM<sup>−</sup>, CD19<sup>hi</sup>-lgM<sup>−</sup>, and CD19<sup>low</sup>-lgM<sup>−</sup> cell populations, bone marrow cells from one to three Hcκ mice were pooled and stained with Abs to mCD45, hCD3, and hCD11c (for the dump gate) and to hCD45, hCD19, and hlgM (with Fab’ anti-IgM Ab). Cells were sorted using a MoFlo XDP (Beckman Coulter) cell sorter. For the enrichment of total bone marrow B cells, pooled bone marrow cells from one to three mice for each strain were incubated with biotinylated Abs to mCD45 and hCD3 and washed three times in staining buffer, and then incubated with anti-biotin beads (Miltenyi Biotec) for 15 min in a refrigerator followed by three washes in MACS buffer (1× PBS, 2 mM EDTA, and 0.5% BSA). Cells were loaded on an autoMACS (Miltenyi Biotec) with a “depletes” program. The negative cell fractions were collected, and a sample was stained with Abs for hCD45, mCD45, hCD3, and hCD19 to check purity. All sorted populations were >85% pure.

IC staining. Cells were stained with Abs to extracellular (EC) proteins as described above in the section “Abs and flow cytometry” and then fixed with 2% formaldehyde for either 5 min at 37°C or 20 min at room temperature (RT). Fixed cells were washed twice in staining buffer (PBS, 1% BSA, and 0.1% Na Azide) and then incubated with either Triton permeabilization buffer (0.5% BSA, 2 mM EDTA, and 0.1% Triton-X 100 in PBS) for 1 h on ice or saponin permeabilization buffer (0.5% BSA and 0.5% saponin in PBS) for 15 min at RT (these methods were interchangeable). Cells were then stained with Abs for IgM, IgG, Igκ, or Igλ (described in “Abs and flow cytometry”) for 30 min in the dark at RT followed by five washes in staining or saponin buffer.
alkaline buffer (Sigma-Aldrich), 5 mM MgCl₂, 1 mM Triton for 1.5 h in the dark at RT. Plates were washed four times in PBS/0.1% Tween followed by blocking for 1–2 h at RT with PBS, 1% BSA, and 0.1% Na Azide buffer, followed by three additional washes. Sera were added to plates with threefold serial dilutions starting at 1:10. Standard hlgM or hlgG was added to plates at 5 µg/ml with threefold serial dilutions. Plates were then incubated overnight at 4°C and washed in the morning five times. This was followed by the addition of a 1:500 dilution of secondary alkaline phosphatase (AP)–conjugated Abs, mouse anti-hlgM (UHB) or hlgG (H2), and the plates were incubated for 2 h at 37°C. After washing five times, 100 µl of developing buffer (AP substrate p-nitrophenyl phosphate; Sigma–Aldrich) was added per well, and light absorbance was measured at OD₄₅₀ with a VersaMax plate reader (Molecular Devices). To ensure consistency, total hlgM and hlgG were further measured using polyclonal Abs as previously described (Lang et al., 2011). They were also calculated by summing the κ- and λ-containing IgM and IgG concentrations. The total IgM and IgG concentrations in Fig. 5 A are the mean of these three independent measurements. Only samples with >0.5 µg/ml hlgM or >10 µg/ml hlgG were included in the respective analyses. For detection of rat IgG₁ (transgene product) in sera, an ELISA was performed similar to the hlgM or IgG polyclonal methods described previously (Lang et al., 2011) except using a goat anti–rat IgG₁ as the coating and secondary Abs.

**ELISPOT.** EIA/RIA 96-well plates (Corning) were coated with goat anti–human κ or λ Abs at 10 µg/ml (2000-01, 2070-01; SouthernBiotech) in PBS and left overnight at 4°C, washed three times with PBS, and blocked with PBS/1% gelatin for 2 h at RT. 10 × 10⁶ spleen cells from hu-mice were resuspended in 400 µl RPMI media supplemented with 10% FBS, GlutaMAX, pen/strep, β-ME, and 10% protein G–absorbed FBS. 400-µl cell suspensions were added to plates at 5 µg/ml with threefold serial dilutions starting at 1:10. Standard hIgM or hIgG was added to plates at 5 µg/ml with threefold serial dilutions. Plates were then incubated overnight at 4°C and washed in the morning five times. This was followed by the addition of a 1:500 dilution of secondary alkaline phosphatase (AP)–conjugated Abs, mouse anti-hlgM (UHB) or hlgG (H2), and the plates were incubated for 2 h at 37°C. After washing five times, 100 µl of developing buffer (AP substrate p-nitrophenyl phosphate; Sigma–Aldrich) was added per well, and light absorbance was measured at OD₄₅₀ with a VersaMax plate reader (Molecular Devices). To ensure consistency, total hlgM and hlgG were further measured using polyclonal Abs as previously described (Lang et al., 2011). They were also calculated by summing the κ- and λ-containing IgM and IgG concentrations. The total IgM and IgG concentrations in Fig. 5 A are the mean of these three independent measurements. Only samples with >0.5 µg/ml hlgM or >10 µg/ml hlgG were included in the respective analyses. For detection of rat IgG₁ (transgene product) in sera, an ELISA was performed similar to the hlgM or IgG polyclonal methods described previously (Lang et al., 2011) except using a goat anti–rat IgG₁ as the coating and secondary Abs.

**Analysis of Igκ rearrangements.** Vκ-Jκ rearrangements were amplified on genomic DNA isolated from CD20⁺κ⁺ cells sorted with a MoFlo XDP cell sorter from the spleen of Hcκ⁺ and Hcκ⁻ hu-mice (cells were pooled from three animals per group). The amplification of Vκ-Jκ rearrangements was performed with a semi-nested PCR protocol in two rounds. Round one was executed on genomic DNA with the mix of 5’ primers Lvk1/2, ATGAGGCTCCCYGTCAGCTGCT GG; Lvk3, CTCCTCCCTCTGTCTCTGGCT CCCAG; and Lvk4, ATTTCTCTGGTCTGCTGGATCTC TG (Tiller et al., 2008); and 3’ primers Jκ1/2/4, ACT CAGTTTGTATYTCASCTTTGTTGCC; Jκ3, GTAAC TAC GTTTGATATCCACTTGTTGCC; and Jκ5, ACTTACG TTAATCTCCAGTCTGTGCC (Küppers et al., 1993) for 35 cycles, each consisting of 30 s at 94°C, 45 s at 57°C, and 2 min at 72°C. Round two was performed on 2-µl PCR reaction from round one and with the mix of 5’ primers Vk1, TGATGTGCAGATCRCRWGTGACCCAGTCTGCCW TC; Vk2, TGATGTGCAGACAGWCTCCACCTCCCTTGC YCCGTCA; Vk3, TGATGTGCAGACTCCAGSCACCTCG TCTKGTGCCTC; Vk4, TGATGTGCAGACTCCCTG GC TGTGCTCTGGG; Vk5, TGATGTGCAGACTCCCTCCA.
GCATTCACTGACGCA; and Vκ6, TGATGTCGACTTY
CTCTCTGTGACTTCARRGGAG (Küppers et al., 1993) and the 3′ Jκ primers listed above for 45 cycles, each consisting of 30 s at 94°C, 45 s at 57°C, and 30 s at 72°C. PCR products were purified from an agarose gel and cloned into the TOPO TA vector (Invitrogen). DNA inserts were sequenced.

Serum injections. Frozen serum samples from several Hκc−/−hu-mice were thawed and pooled (mean concentration of 24 µg/ml hIgM and 1,088 µg/ml hIgG). The pooled sera was injected (∼200 µl per mouse) into the tail vein of intact (nonhumanized) Hκc−/− or Hκc+ mice either neat or at a 1:10 dilution. Uninjected mice served as controls. Sera were collected the next day and tested for the presence of hIgκ, hIgλ, hIgM, and hIgG by ELISA as described above in the “ELISAs” section.

Statistical analysis. Statistical significance was assessed using Prism software (GraphPad Software), with a two-tailed Student’s t test of equal variance or a Welch correction when appropriate. Statistical analysis of Vκ and Jκ usage was performed by Z-test. To analyze differences among unique CB-derived hu-mice, data were analyzed using ANOVA with a Tukey post hoc test.

Acknowledgments

We thank Dr. Michel Nussenzweig for the gift of Igκκ+ mice. We also thank the National Jewish Health (NJH) and University of Colorado Anschutz Medical Center (AMC) Cancer Center flow cytometry facilities for assistance with cell sorting and analysis and the Biological Resource Center at NJH and the Vavarium at the University of Colorado AMC for assistance with mouse husbandry. We are very grateful to all members of our laboratories for the numerous useful discussions.

This work was supported by the National Institutes of Health with R21-AI073629 (to R. Pelanda) and R01-AI59714 (to D. Nemazee) grants, the Arthritis Foundation Prism software (GraphPad Software), with a two-tailed Student’s t test of equal variance or a Welch correction when appropriate. Statistical analysis of Vκ and Jκ usage was performed by Z-test. To analyze differences among unique CB-derived hu-mice, data were analyzed using ANOVA with a Tukey post hoc test.

References

Ait-Azzouzene, D., L. Verkoczy, J. Peters, A. Gavin, P. Skog, J.L. Vela, and D. Nemazee. 2005. An immunoglobulin Cκ-reactive single chain antibody fusion protein induces tolerance through receptor editing in a normal polyclonal immune system. J. Exp. Med. 201:817–828. http://dx.doi.org/10.1084/jem.20041854

Ait-Azzouzene, D., P. Skog, M. Retter, V. Kouskoff, M. Hertz, J. Lang, J. Krench, M. Chambly, D. Melamud, J. Sudarika, et al. 2004. Tolerance-induced receptor selection: scope, sensitivity, locus specificity, and relationship to lymphocyte-positive selection. Immunity. Rev. 197:219–230. http://dx.doi.org/10.1111/j.1055-2896.2004.0106.x

Ait-Azzouzene, D., L. Verkoczy, B. Duong, P. Skog, A.L. Gavin, and D. Nemazee. 2006. Split tolerance in peripheral B cell subsets in mice expressing a low level of Igκ-reactive ligand. J. Immunol. 176:939–948. http://dx.doi.org/10.4049/jimmunol.176.2.939

Akchina, R., 2013. Human immune responses and potential for vaccine assessment in humanized mice. Cart. Opin. Immunol. 25:403–409. http://dx.doi.org/10.1016/j.coi.2013.03.009

Andrews, S.F., Q. Zhang, S. Lim, L. Li, J.H. Lee, N.Y. Zheng, M. Huang, W.M. Taylor, A.D. Farris, D. Nemazee, et al. 2013. Global analysis of B cell selection using an immunoglobulin light chain-mediated model of autoreactivity. J. Exp. Med. 210:125–142. http://dx.doi.org/10.1084/jem.20120525

Bräuninger, A., T. Goossens, K. Rajewsky, and R. Kuppers. 2001. Regulation of immunoglobulin light chain gene rearrangements during early B cell development in the human. Eur. J. Immunol. 31:3631–3637. http://dx.doi.org/10.1002/1521-4141(200112)31:12<3631::AID-JIMMU3631>3.0.CO;2-L

Casellas, R., T.A. Shih, M. Kleineveldt, J. Rakonjac, D. Nemazee, K. Rajewsky, and M.C. Nussenzweig. 2001. Contribution of receptor editing to the antibody repertoire. Science. 291:1541–1544. http://dx.doi.org/10.1126/science.1056600

Choi, B., E. Chun, M. Kim, S.T. Kim, K. Yoon, K.Y. Lee, and S.J. Kim. 2011. Human B cell development and antibody production in humanized NOD/SCID/IL-2Rγ−/− (NSG) mice conditioned by busulfan. J. Clin. Immunol. 31:253–264. http://dx.doi.org/10.1007/s10875-010-9478-2

Dir, R., S.K. McCray, and S.H. Clarke. 2008. B cell receptor affinity and B cell subset identity integrate to define the effectiveness, affinity threshold, and mechanism of energy. J. Immunol. 181:3834–3840. http://dx.doi.org/10.4049/jimmunol.181.6.3834

Doyle, C.M., J. Han, M.G. Weigert, and E.T. Prak. 2006. Consequences of receptor editing at the Jκ locus: Multireactivity and light chain secrertion. Proc. Natl. Acad. Sci. USA. 103:11264–11269. http://dx.doi.org/10.1073/pnas.0604053103

Duong, B.H., T. Ota, D. Ait-Azzouzene, M. Aoki-Ota, J.L. Vela, C. Huber, K. Walsh, A.L. Gavin, and D. Nemazee. 2010. Peripheral B cell tolerance and function in transgenic B cells expressing an IgD superantigen. J. Immunol. 184:4143–4158. http://dx.doi.org/10.4049/jimmunol.0903864

Duong, B.H., T. Ota, M. Aoki-Ota, A.B. Cooper, D. Ait-Azzouzene, J.L. Vela, A.L. Gavin, and D. Nemazee. 2011. Negative selection by IgM superantigen defines a B cell central tolerance compartment and reveals mutations allowing escape. J. Immunol. 187:5596–5605. http://dx.doi.org/10.4049/jimmunol.1102479

Fournier, E.M., M.G. Velez, K. Leahy, C.L. Swanson, A.V. Rubtsov, R.M. Torres, and R. Pelanda. 2012. Dual-reactive B cells are autoreactive and highly enriched in the plasmablast and memory B cell subsets of autoimmune mice. J. Exp. Med. 209:1797–1812. http://dx.doi.org/10.1084/jem.20120332

Goodnow, C.C., J.G. Cyster, S.B. Hartley, S.E. Bell, M.P. Cooke, J.I. Healy, S. Akkaraju, J.C. Rathmell, S.L. Pogue, and K.P. Shokat. 1995. Self-tolerance checkpoints in B lymphocyte development. Annu. Rev. Immunol. 13:279–368. http://dx.doi.org/10.1001/joai.1995.100184

Goodnow, C.C., C.G. Vinnesa, K.L. Randall, F. Mackay, and R. Brink. 2010. Control systems and decision making for antibody production. Nat. Immunol. 11:681–688. http://dx.doi.org/10.1038/ni.1900

Gorantla, S., H. Sneller, L. Walters, J.G. Sharp, S.J. Parruccello, J.T. West, C. Wood, S. Dewhurst, H.E. Gendelman, and L. Poluektova. 2007. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2−/−γ−/− mice. J. Virol. 81:2700–2712. http://dx.doi.org/10.1128/JI.0010-06

Grundherr, A., R. Fuc, A. Nohreba, J. Andersson, and A. Coutsinho. 1994. Negative selection of multireactive B cell clones in normal adult mice. Eur. J. Immunol. 24:1345–1352. http://dx.doi.org/10.1002/eji.1830240616

Halverson, R., R.M. Torres, and R. Pelanda. 2004. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat. Immunol. 5:645–650. http://dx.doi.org/10.1038/ni1076
Siminovitch, K.A., A. Bakhshi, P. Goldman, and S.J. Korsmeyer. 1985. A uniform deleting element mediates the loss of κ genes in human B cells. Nature. 316:260–262. http://dx.doi.org/10.1038/316260a0

Taneja, V., and C.S. David. 2010. Role of HLA class II genes in susceptibility/resistance to inflammatory arthritis: studies with humanized mice. Immunol. Rev. 233:62–78. http://dx.doi.org/10.1111/j.0105-2896.2009.00858.x

Teodorovic, L.S., C. Babolin, S.L. Rowland, S.A. Greaves, D.P. Baldwin, R.M. Torres, and R. Pelanda. 2014. Activation of Ras overcomes B-cell tolerance to promote differentiation of autoreactive B cells and production of autoantibodies. Proc. Natl. Acad. Sci. USA. 111:E2797–E2806. http://dx.doi.org/10.1073/pnas.1402159111

Tiegs, S.L., D.M. Russell, and D. Nemazee. 1993. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177:1009–1020. http://dx.doi.org/10.1084/jem.177.4.1009

Tiller, T., E. Meffre, S. Yurasov, M. Tsuji, M.C. Nussenzweig, and H. Wardemann. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods. 329:112–124. http://dx.doi.org/10.1016/j.jim.2007.09.017

Traggiai, E., L. Chicha, L. Mazzucchelli, L. Bronz, J.C. Piffaretti, A. Lanzavecchia, and M.G. Manz. 2004. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 304:104–107. http://dx.doi.org/10.1126/science.1093993

Tze, L.E., E.A. Baness, K.L. Hippen, and T.W. Behrens. 2000. Ig light chain receptor editing in anergic B cells. J. Immunol. 165:6796–6802. http://dx.doi.org/10.4049/jimmunol.165.12.6796

Verkoczy, L., D. Ait-Azzouzene, P. Skog, A. Märtensson, J. Lang, B. Duong, and D. Nemazee. 2005. A role for nuclear factor kappa B/rel transcription factors in the regulation of the recombinase activator genes. Immunity. 22:519–531. http://dx.doi.org/10.1016/j.immuni.2005.03.006

Verkoczy, L., B. Duong, P. Skog, D. Ait-Azzouzene, K. Puri, J.L. Vela, and D. Nemazee. 2007. Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection. J. Immunol. 178:6332–6341. http://dx.doi.org/10.4049/jimmunol.178.10.6332

Villaudy, J., R. Schotte, N. Legrand, and H. Spits. 2014. Critical assessment of human antibody generation in humanized mouse models. J. Immunol. Methods. 410:18–27. http://dx.doi.org/10.1016/j.jim.2014.06.010

Wardemann, H., S. Yurasov, A. Schaefer, J.W. Young, E. Meffre, and M.C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. Science. 301:1374–1377. http://dx.doi.org/10.1126/science.1086907

Wardemann, H., J. Hammersen, and M.C. Nussenzweig. 2004. Human autoantibody silencing by immunoglobulin light chains. J. Exp. Med. 200:191–199. http://dx.doi.org/10.1084/jem.20040818

Wen, L., J. Brill-Dashoff, S.A. Shinton, M. Asano, R.R. Hardy, and K. Hayakawa. 2005. Evidence of marginal-zone B cell-positive selection in spleen. Immunity. 23:297–308. http://dx.doi.org/10.1016/j.immuni.2005.08.007

Yuan, J., C.K. Nguyen, X. Liu, C. Kanellopoulou, and S.A. Muljo. 2012. Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis. Science. 335:1195–1200. http://dx.doi.org/10.1126/science.1216537

Zhou, Y., Y.S. Li, S.R. Bandi, L. Tang, S.A. Shinton, K. Hayakawa, and R.R. Hardy. 2015. Lin28b promotes fetal B lymphopoiesis through the transcription factor Arid3a. J. Exp. Med. 212:569–580. http://dx.doi.org/10.1084/jem.20141510